Relevant bibliographies by topics / 826 / Journal articles
To see the other types of publications on this topic, follow the link: 826.

Journal articles on the topic '826'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '826.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Aqua, K., J. Gimbel, N. Singla, B. Galer, T. Ma, and H. Ahdieh. "(826)." Journal of Pain 7, no. 4 (April 2006): S57. http://dx.doi.org/10.1016/j.jpain.2006.01.228.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mayes, L., M. Allshouse, G. Page, R. Edwards, B. Goodin, and L. McGuire. "(826)." Journal of Pain 8, no. 4 (April 2007): S57. http://dx.doi.org/10.1016/j.jpain.2007.02.233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Garry, Jonah, Kelly Casey, Lianne Wachira, Therese Kling, Angela Regensburg, Colleen McElroy, and Albert Chi. "826." Critical Care Medicine 41 (December 2013): A206. http://dx.doi.org/10.1097/01.ccm.0000440064.37829.6a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jie, Chen, Qian Lu, and Hai yan Zhang. "826." Critical Care Medicine 42 (December 2014): A1559. http://dx.doi.org/10.1097/01.ccm.0000458323.20795.ff.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rubio, Marcos, Enrique Garcia, Maria De La Torre, Raquel del Olmo, Noelia Gonzalez, Beatriz Nieto, Tomasa Martinez, et al. "826." Critical Care Medicine 47 (January 2019): 392. http://dx.doi.org/10.1097/01.ccm.0000551575.44901.c5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pannu, Sonal, Steven Holets, Man Li, Alberto Marquez, Rahul Kashyap, Mazen O. Al-qadi, Gregory Wilson, and Ognjen Gajic. "826." Critical Care Medicine 40 (December 2012): 1–328. http://dx.doi.org/10.1097/01.ccm.0000425041.30516.a2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "826." Neurosurgery 53, no. 2 (August 2003): 513–14. http://dx.doi.org/10.1097/00006123-200308000-00160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Carroll, Christopher, Viren Kaul, Kathleen Sala, and Neha Dangayach. "826." Critical Care Medicine 48 (January 2020): 393. http://dx.doi.org/10.1097/01.ccm.0000631444.67042.56.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Magnuson, Ryan, David Lent, Anthony Pietropaoli, Mark Ott, E. Kate Valcin, Samad Rasul, and Michael Apostolakos. "826." Critical Care Medicine 43 (December 2015): 208. http://dx.doi.org/10.1097/01.ccm.0000474654.31694.73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Davis, Irene. "826." Medicine & Science in Sports & Exercise 39, Supplement (May 2007): S72. http://dx.doi.org/10.1249/01.mss.0000273185.04754.5f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Wang Kewei, J., J. U. N. Qiu, Y. Zhu, H. Luo, and Z. Xiao. "ABSTRACT 826." Pediatric Critical Care Medicine 15 (May 2014): 184. http://dx.doi.org/10.1097/01.pcc.0000449552.74770.b5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Treugut, H. "Fall 826." DMW - Deutsche Medizinische Wochenschrift 105, no. 45 (July 28, 2009): e179-e180. http://dx.doi.org/10.1055/s-0029-1237081.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Fahey, Mark R. "Algorithm 826." ACM Transactions on Mathematical Software 29, no. 3 (September 2003): 326–36. http://dx.doi.org/10.1145/838250.838256.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Conway, D. A., S. Talebian, N. Noyes, L. C. Krey, and J. A. Grifo. "P-826." Fertility and Sterility 86, no. 3 (September 2006): S440. http://dx.doi.org/10.1016/j.fertnstert.2006.07.1213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Grimshaw, John, and Martyn Rix. "826. HALESIA MACGREGORII." Curtis's Botanical Magazine 33, no. 1 (February 2016): 60–66. http://dx.doi.org/10.1111/curt.12136.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Mund, Debra Fohrman, Lawrence Yao, Yao Shi Fu, and Jeffrey J. Eckardt. "Case report 826." Skeletal Radiology 23, no. 2 (February 1994): 139–41. http://dx.doi.org/10.1007/bf00563211.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Heath, A. B., and P. J. Gaffney. "A Collaborative Study to Establish the Second International Standard for Streptokinase." Thrombosis and Haemostasis 64, no. 02 (1990): 267–69. http://dx.doi.org/10.1055/s-0038-1647298.

Full text
Abstract:
SummaryAn International Standard for Streptokinase - Streptodomase (62/7) has been used to calibrate high purity clinical batches of SK since 1965. An international collaborative study, involving six laboratories, was undertaken to replace this standard with a high purity standard for SK. Two candidate preparations (88/826 and 88/824) were compared by a clot lysis assay with the current standard (62/7). Potencies of 671 i.u. and 461 i.u. were established for preparations A (88/826) and B (88/824), respectively.Either preparation appeared suitable to serve as a standard for SK. However, each ampoule of preparation A (88/826) contains a more appropriate amount of SK activity for potency testing, and is therefore preferred. Accelerated degradation tests indicate that preparation A (88/826) is very stable.The high purity streptokinase preparation, coded 88/826, has been established by the World Health Organisation as the 2nd International Standard for Streptokinase, with an assigned potency of 700 i.u. per ampoule.
APA, Harvard, Vancouver, ISO, and other styles
18

 . "826 Benoemingen, Aftredens E.D." Zorg en Financiering 7, no. 6 (June 2008): 102. http://dx.doi.org/10.1007/bf03097062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Ohtsuka, T., and S. Streif. "Correction to “Commutativity of Immersion and Linearization” [Apr 09 826-829]." IEEE Transactions on Automatic Control 54, no. 5 (May 2009): 1176. http://dx.doi.org/10.1109/tac.2009.2021504.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Röthel, Anne. "Vorsätzliche sittenwidrige Schädigung (§ 826 BGB)." JURA - Juristische Ausbildung 43, no. 3 (February 3, 2021): 258–64. http://dx.doi.org/10.1515/jura-2020-2717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Opinión Pública, Instituto Universitario de. "Los salvadoreños y el proceso electoral de 2003." ECA: Estudios Centroamericanos 57, no. 647 (September 30, 2002): 823–26. http://dx.doi.org/10.51378/eca.v57i647.5579.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Wang, Wenxing, Yang Yang, Enjun Cheng, Manchun Zhao, Haifeng Meng, Dongsheng Liu, and Dejian Zhou. "Correction: A pH-driven, reconfigurable DNA nanotriangle." Chemical Communications 52, no. 70 (2016): 10696. http://dx.doi.org/10.1039/c6cc90352e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Kotova, A. V. "On sources of the similes in Statius’ “Achilleid”: 1, 159–166, 823–826." Indo-European Linguistics and Classical Philology, no. 25 (2021): 627–36. http://dx.doi.org/10.30842/ielcp230690152539.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Kanesaki, Tomohiko, Sadaaki Maeda, Yasuhiro Ooi, Makio Saeki, Ken Matsumoto, Masayoshi Sakuda, and Kihachi Saito. "826 Morphine prevents peroxynitrite-induced apoptosis." Neuroscience Research 28 (January 1997): S108. http://dx.doi.org/10.1016/s0168-0102(97)90288-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

 . "826 Marktwerking Leidt Niet Tot Klantvriendelijkheid." Zorg en Financiering 8, no. 6 (June 2009): 88. http://dx.doi.org/10.1007/bf03098495.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Ehrlich, Veronika, Peter Leidenmuehler, Barbara Dietrich, Gerald Hoebarth, Tanja Ruthsatz, Peter L. Turecek, Martin Wolfsegger, et al. "Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product." Blood 128, no. 22 (December 2, 2016): 4977. http://dx.doi.org/10.1182/blood.v128.22.4977.4977.

Full text
Abstract:
Abstract Hemophilia A is a rare genetic bleeding disorder caused by missing or defective factor VIII (FVIII), a crucial factor in blood coagulation. Baxalta Innovations / Shire is currently developing SHP 826 (BAX 826), as the next generation EHL rFVIII replacement for the treatment of hemophilia A. SHP 826 is the first EHL rFVIII to utilize novel technology in which polysialic acid (PSA) is conjugated to Baxalta's licensed rFVIII product (Advate) to extend the circulation half-life of FVIII. The potential toxicity of SHP 826 was evaluated in Sprague Dawley rats and cynomolgus monkeys. Acute toxicity was assessed in a dose-escalation study in monkeys that were intravenously administered 350 and 1800 IU rFVIII/kg SHP 826. Repeat dose toxicity was assessed in rats at doses of 80, 350, and 800 IU rFVIII/kg, in monkeys at doses of 800 IU rFVIII/kg every 5 days for 4 weeks, and in monkeys at doses of 80, 350, or 600 IU rFVIII/kg every five days for 31 days. Cardiovascular and respiratory safety was assessed in one of the repeat dose toxicity studies in monkeys. The thrombogenic potential of SHP 826 was evaluated after a single intravenous administration in rabbits (900 rFVIII/kg BW) using a stasis model developed by Wessler et al. (1959). The licensed rFVIII product was used as a comparator in the acute toxicity study and in the Wessler test. Parameters evaluated included local tolerance at the injection site, body weight, clinical pathology, blood gas analysis, analysis of neutralizing and binding antibodies in plasma, organ weight, necropsy observation, and histopathological evaluation. In addition, seminology (epididymal and testicular sperm) was assessed in rats, and urinalysis, ophthalmic and telemetric cardiovascular examination and respiratory rate measurement was performed in monkeys. SHP 826 showed a favorable safety/toxicity profile in both species used, with no abnormalities directly caused by test item administration noted in vivo or during clinical or histopathological examination. The NOAEL was set to the highest dose tested in each study (i.e. 800 IU rFVIII/kg BW in rats and 600 IU rFVIII/ kg BW in monkeys). Toxicokinetic evaluation indicated dose proportional PK. Exposure to FVIII decreased after repeated treatments due to appearance of anti-FVIII antibodies in both species. Development of anti-FVIII antibodies is an expected immune response after repeated application of heterologous proteins, and is not predictive of any potential for triggering development of anti-FVIII antibodies in humans. Safety pharmacology studies with SHP 826 revealed no evidence of thrombogenic potential in rabbits. SHP 826 administered intravenously was well tolerated in conscious telemetered cynomolgous monkeys (part of the repeat dose toxicity study) and did not cause any adverse clinical, cardiovascular, or respiratory effects. The results of these safety studies indicate sufficient safety margins to support the anticipated maximum clinical dose, and therefore entry into clinical development. Disclosures Ehrlich: Shire: Employment. Leidenmuehler:Shire: Employment. Dietrich:Shire: Employment. Hoebarth:Shire: Employment. Ruthsatz:Shire: Employment. Turecek:Shire: Employment. Wolfsegger:Shire: Employment, Equity Ownership. Weber:Shire: Employment. Gritsch:Shire: Employment. Hoellriegl:Shire: Employment. Turecek:Shire: Employment.
APA, Harvard, Vancouver, ISO, and other styles
27

Förster, Christian. "Der Schwarze Ritter – § 826 BGB im Gesellschaftsrecht." Archiv für die civilistische Praxis 209, no. 3-4 (2009): 398. http://dx.doi.org/10.1628/000389909788930098.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Nemade, H., A. Rao, J. Makanjoula, and P. Thompson. "826 Historical aspects of ultrasound in urology." European Urology Supplements 11, no. 1 (February 2012): e826-e826a. http://dx.doi.org/10.1016/s1569-9056(12)60823-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Whelan, Anna, Seema Ghelani, Elizabeth Majewski, Melissa Wagner-Schuman, Sondra Summers, and Quetzal Class. "826: Inpatient psychiatric admissions and obstetric outcomes." American Journal of Obstetrics and Gynecology 220, no. 1 (January 2019): S539. http://dx.doi.org/10.1016/j.ajog.2018.11.849.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

LIDDLE, K., G. GILMET, and J. BALDWIN. "826 Cutaneous prick testing with duotip-test." Journal of Allergy and Clinical Immunology 97, no. 1 (January 1996): 389. http://dx.doi.org/10.1016/s0091-6749(96)81044-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

McCrory, P. R. "CONCUSSIVE IMPACT CONVULSIONS IN AUSTRALIAN FOOTBALL 826." Medicine &amp Science in Sports &amp Exercise 29, Supplement (May 1997): 144. http://dx.doi.org/10.1097/00005768-199705001-00825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Vitaz, Todd W., Jennifer Jenks, Laura McIlvoy, George Raque, and Christopher B. Shields. "826 Outcome after Moderate Closed Head Injury." Neurosurgery 47, no. 2 (August 1, 2000): 536. http://dx.doi.org/10.1097/00006123-200008000-00174.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

 . "826 Hoogervorst: Beroepsgeheim Arts Gewaarborgd In ZVW." Zorg en Financiering 4, no. 5 (May 2005): 111–12. http://dx.doi.org/10.1007/bf03090944.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

 . "826 Experiment Fysiotherapie Met Een Jaar Verlengd." Zorg en Financiering 5, no. 6 (June 2006): 71. http://dx.doi.org/10.1007/bf03092651.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Jordan, Jennifer L., Jason R. Foley, and Clive R. Siviour. "Mechanical properties of Epon 826/DEA epoxy." Mechanics of Time-Dependent Materials 12, no. 3 (July 26, 2008): 249–72. http://dx.doi.org/10.1007/s11043-008-9061-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Gill, Charles J., Jesse J. Jackson, Lynn S. Gerckens, Barbara A. Pelak, Randall K. Thompson, Jon G. Sundelof, Helmut Kropp, and H. Rosen. "In Vivo Activity and Pharmacokinetic Evaluation of a Novel Long-Acting Carbapenem Antibiotic, MK-826 (L-749,345)." Antimicrobial Agents and Chemotherapy 42, no. 8 (August 1, 1998): 1996–2001. http://dx.doi.org/10.1128/aac.42.8.1996.

Full text
Abstract:
ABSTRACT MK-826 (formerly L-749,345), is a potent 1-β-methyl carbapenem with a long half-life and broad spectrum of activity. This compound is presently in phase-II clinical trials. Its activity against a number of gram-positive and gram-negative organisms was compared to those of imipenem (IPM) and eight other β-lactam agents in two in vivo murine infection models. The distribution in tissue and pharmacokinetic properties of MK-826 and ceftriaxone (CTRX) were also evaluated in CD-1 mice following a single intraperitoneal dose (10 mg/kg of body weight). In addition, concentrations in plasma as well as biliary and urinary recovery of MK-826 were compared to that of CTRX in a cannulated rat model. In a localized murine thigh infection model, MK-826 and IPM were superior to a variety of β-lactam antibiotics in reduction ofStaphylococcus aureus CFU compared with results from nontreated controls (eliminating ≥4 log10 CFU). Similar activities of IPM and MK-826 were observed in a gram-positive bacterial murine systemic infection model. While IPM demonstrated greater efficacy than MK-826 against Enterobacter cloacae (50% effective doses [ED50s] of 0.062 and 0.227 mg/kg, respectively) and Pseudomonas aeruginosa (ED50s of 0.142 and 3.0 mg/kg, respectively) systemic infections, MK-826 was 8- to 350-fold more efficacious than IPM against all other gram-negative organisms in this infection model. In mice, MK-826 demonstrated a higher peak concentration in serum (62.8 versus 42.6 μg/ml) and a larger area under the curve (AUC) (150.8 versus 90.0 μg · hr/ml) than CTRX. The concentrations of MK-826 and CTRX in serum declined slowly, with levels of 3.6 and 2.0 μg/ml remaining, respectively, at 6 h posttreatment. The rat pharmacokinetic model showed the average AUC of MK-826 to be greater than that of CTRX (284 versus 142 μg · hr/ml) following a single 10-mg/kg dose. Also, a half-life of MK-826 longer than that of CTRX (3.2 versus 2.3 h) was observed in this species. The total amount of drug excreted in the bile in 8 h was greater for CTRX (55 to 64% of the dose) than for MK-826 (6 to 12.5% of the dose). Urinary recovery was similar for both antibiotics, with 16 to 18% of the dose recovered over an 8-h period. This excellent broad-spectrum in vivo efficacy of MK-826, together with advantageous pharmacokinetics, supports the argument for its further clinical development.
APA, Harvard, Vancouver, ISO, and other styles
37

Scovassi, AI, and A. Torriglia. "Activation of DNA-degrading enzymes during apoptosis." European Journal of Histochemistry 47, no. 3 (June 26, 2009): 185. http://dx.doi.org/10.4081/826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Utz, Christian. "Nicholas Cook, Beyond the Score: Music as Performance, New York: Oxford University Press 2013." Zeitschrift der Gesellschaft für Musiktheorie [Journal of the German-Speaking Society of Music Theory] 12, no. 2 (2015): 275–85. http://dx.doi.org/10.31751/826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

M. Lunt, Barry, Joseph J. Ekstrom, Eydie Lawson, Reza Kamali, Jacob Miller, Sandra Gorka, and Han Reichgelt. "Defining the IT Curriculum: The Results of the Past 3 Years." Issues in Informing Science and Information Technology 2 (2005): 259–70. http://dx.doi.org/10.28945/826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

FARIA, Fernanda Augusta Marques Pinheiro, Letícia Caixeta Vieira RIBEIRO, Alexandra Azevedo de CARVALHO, and Jeanete Moussa ALMA. "Análise sobre a opção de curso de graduação em Tecnologia em Cosmetologia e Estética pelas discentes da Unincor doi: http://dx.doi.org/10.5892/ruvrv.2013.111.277288." Revista da Universidade Vale do Rio Verde 11, no. 1 (July 30, 2013): 277. http://dx.doi.org/10.5892/826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Namiki, T., Y. Aoki, Y. Yamada, T. D. Matsuda, H. Sugawara, and H. Sato. "Erratum to “La-substitution study on filled-skutterudite PrFe4P12” [Physica B 312–313 (2002) 825–826]." Physica B: Condensed Matter 324, no. 1-4 (November 2002): 430. http://dx.doi.org/10.1016/s0921-4526(02)01533-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Davidoff, F., C. D. DeAngelis, J. M. Drazen, J. Hoey, L. Hojgaard, R. Horton, S. Kotzin, et al. "Sponsorship, authorship, and accountability.11N Engl J Med 2001;345:825–826 and JAMA 2001;286:1232–1233." American Journal of Ophthalmology 133, no. 1 (January 2002): 174. http://dx.doi.org/10.1016/s0002-9394(01)01343-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Aso, Yoshio, Motoaki Kitagawa, Atsushi Tajima, Kazuo Suzuki, Yoshihisa Ohtawara, Yoshio Ohmi, Nobutaka Ohta, et al. "STATISTICAL AND CLINICAL OBSERVATIONS OF 826 STONE PATIENTS." Japanese Journal of Urology 79, no. 10 (1988): 1639–45. http://dx.doi.org/10.5980/jpnjurol1928.79.10_1639.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Benz, Jared, and Dale Lent. "Abstract #826: Alcoholic Ketoacidosis Masquerading as Diabetic Ketoacidosis." Endocrine Practice 22 (May 2016): 174. http://dx.doi.org/10.1016/s1530-891x(20)45160-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Nattiv, A., and G. Green. "826 LIFESTYLE BEHAVIORS OF COLLEGIATE ATHLETES BY SPORT." Medicine & Science in Sports & Exercise 25, Supplement (May 1993): S148. http://dx.doi.org/10.1249/00005768-199305001-00828.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Hall, Judith G. "826 GENETIC HETEROGENEITY IN ARTHROGRYPOSIS (MULTIPLE CONGENITAL CONTRACTURES)." Pediatric Research 19, no. 4 (April 1985): 248A. http://dx.doi.org/10.1203/00006450-198504000-00856.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

KURIBAYASHI, Kaori, and Shoji TAKEUCHI. "826 Electroformation of Giant Liposomes in Microfluidic Channels." Proceedings of the JSME annual meeting 2005.7 (2005): 55–56. http://dx.doi.org/10.1299/jsmemecjo.2005.7.0_55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

OKUDA, Ichiro, Hiroshi MATSUHISA, and Naohide TOMITA. "826 The Influence of Swing on Tennis Elbow." Proceedings of Conference of Kansai Branch 2001.76 (2001): _8–57_—_8–58_. http://dx.doi.org/10.1299/jsmekansai.2001.76._8-57_.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Imoto, Akiko, Mana Katori, Toshi-Taka Ikeshoji, Akio Suzumura, Takahisa Yamazaki, Masahiro Sakamoto, and Satoshi Sakimichi. "826 Improvement in Solderability of Surface Modified graphite." Proceedings of the Materials and processing conference 2012.20 (2012): _826–1_—_826–2_. http://dx.doi.org/10.1299/jsmemp.2012.20._826-1_.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Schiviz, Alexandra, Gerald Hoebarth, Martin Wolfsegger, Paolo Rossato, Alfred Weber, Herbert Gritsch, Hanspeter Rottensteiner, et al. "Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys." Blood 126, no. 23 (December 3, 2015): 1073. http://dx.doi.org/10.1182/blood.v126.23.1073.1073.

Full text
Abstract:
Abstract Factor VIII (FVIII) is a critical component of the intrinsic coagulation pathway. Plasma-derived or recombinant (r) FVIII concentrates are used in patients with hemophilia A to provide a FVIII level sufficient to treat and prevent bleeding episodes. Prophylactic FVIII levels can only be maintained by administering several infusions per week. Extended FVIII circulation times would reduce the frequency of infusions, increase patient compliance, reduce the number of bleeds, and offer the possibility to achieve higher trough levels of FVIII. Prolonged circulation can be achieved by modifying the FVIII molecule with hydrophilic polymers, for example with polysialic acid (PSA). BAX 826, Baxalta's polysialylated FVIII is based on ADVATE, a full length recombinant FVIII molecule with an established extensive safety and efficacy profile. The aim of the presented studies was to assess the pharmacokinetic profile of BAX 826 in hemophilia A mice, wild-type rats, and cynomolgus monkeys. Unmodified rFVIII (ADVATE) was used as the reference compound. Test and reference compounds were administered at the same dose. Hemophilia A mice and Sprague Dawley rats were intravenously injected with BAX 826 at a target dose of 200 IU/kg rFVIII, and blood was sampled pre-dose and 5 min to 48 h after administration. Cynomolgus monkeys received a target dose of 350 IU/kg rFVIII and blood sampled 5 min to 120 h after administration. Citrated plasma was prepared and analyzed for FVIII activity (chromogenic), FVIII antigen (ELISA), and PSA-rFVIII concentration. The primary endpoint was area under the curve from administration time to the last quantifiable time point (AUC0-tlast). Mean residence time (MRT) and systemic clearance (CLs) were also assessed. Unless stated otherwise, results for FVIII activity (mice, monkeys) and FVIII antigen (rats) are presented. In mice, the AUC0-tlast for BAX 826 was 20.6 h*IU/mL, which was 2.4 times larger than for ADVATE (8.71 h*IU/mL); MRT was 10.6 h for BAX 826 and 5.8 h for ADVATE. Clearance was lower for BAX 826 (9.4 vs. 22.3 mL/h/kg). In rats, the AUC0-tlast for BAX 826 was 18.0 h*IU/mL, which was 1.8 times larger than for ADVATE (9.9 h*IU/mL). MRT was 12.5 h for BAX 826 and 4.0 h for ADVATE, and CLs was 5.3 and 28.1 mL/h/kg. In monkeys, the geometric mean of AUC0-tlast was 189.0 h*IU/mL for BAX 826 and 39.6 h*IU/mL for ADVATE. MRT was 23.4 and 10.1 h, and CLs was 2.25 and 6.72 mL/h/kg for BAX 826 and ADVATE, respectively. In monkeys, a baseline FVIII activity level was detected and adequately taken into account in calculating pharmacokinetic parameters. Nevertheless, to better follow the pharmacokinetic profile of BAX 826, the polysialylated rFVIII concentration was also assessed using a PSA specific assay. PSA-FVIII was measured in all animals after administration of BAX 826. In summary, pharmacokinetics studies in three animal species provided evidence that modification of ADVATE with PSA increases circulation time and exposure compared with the unmodified protein. Disclosures Schiviz: Baxalta Innovations GmbH: Employment. Hoebarth:Baxalta Innovations GmbH: Employment. Wolfsegger:Baxalta Innovations GmbH: Employment. Rossato:Baxalta Innovations GmbH: Employment. Weber:Baxalta Innovations GmbH: Employment. Gritsch:Baxalta Innovations GmbH: Employment. Rottensteiner:Baxalta Innovations GmbH: Employment. Turecek:Baxalta Innovations GmbH: Employment. Scheiflinger:Baxalta Innovations GmbH: Employment. Hoellriegl:Baxalta Innovations GmbH: Employment. Putz:Baxalta Innovations GmbH: Employment.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic '826' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography